News
-
FUJIFILM Corporation (President: Kenji Sukeno) announced that it will collaborate with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada. It signed a clinical collaboration agreement with MSD International GmbH, effective May 25, for the implementation of a clinical trial that evaluates a combination therapy with […]
-
Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19
FUJIFILM Corporation (President: Kenji Sukeno) has announced that it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for treating patients with COVID-19. To further boost the supply of Avigan, Fujifilm is allocating additional capacity at its FUJIFILM Wako Pure Chemical Co., Ltd. facility in Japan, for production of pharmaceutical intermediates used to manufacture Avigan. In […]
-
FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus. Avigan, approved in Japan for manufacture and sale as an influenza antiviral drug, […]
-
FUJIFILM Corporation (President: Kenji Sukeno) announces that today it will begin to offer contract services of process development and manufacturing of liposome formulations to its partners seeking drug delivery formulations that are designed to deliver the therapeutic to the affected sites. The service will include both small molecule drugs and nucleic acid medicines*1 which are […]
-
FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) is proud to announce the construction completion of a new manufacturing facility (facility name: 701) within its Toyama Second Factory for manufacturing liposome formulations. Liposome is a drug delivery system that has shown promising results in facilitating the drug delivery. The 701 facility is Japan’s first*1 manufacturing facility of liposome formulation capable of commercial-level production, and is due to go operational in February 2020. Liposome formulation contains active ingredient such as drugs in artificially constructed […]
-
FUJIFILM Corporation (President: Kenji Sukeno) announced the start of a U.S. Phase I clinical trial of FF-10850, an anti-cancer agent targeting advanced solid tumors. FF-10850 is a liposome-based agent in which topotecan*1, an approved anti-cancer agent, has been encapsulated in the newly developed liposome. The study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FF-10850. As a drug delivery system (DDS), liposomes are artificially constructed vesicles made from the organic phospholipids which make up cellular membranes and biomembranes. Liposomes […]
-
Fujifilm Commits to Further Research on Nucleic Acid-liposome drug delivery system
FUJIFILM Corporation (President: Kenji Sukeno) announced today that Fujifilm is working towards improving the development of nucleic acid therapeutics by using liposomal drug delivery systems. Fujifilm’s liposomal drug delivery systems are created from its expertise in advanced nanodispersion and analytical technologies. The drug delivery formulation is also used in its anti-cancer drug candidate “FF-10832”, a liposomal gemcitabine formulation, which is being evaluated in a US Phase 1 clinical trial. In support of these continuing efforts, Fujifilm has engaged in a research collaboration with the Anderson Lab at the […]
-
FUJIFILM Corporation (President: Kenji Sukeno) has succeeded in stably encapsulating the anti-cancer agent topotecan*1, approved for the treatment of several solid cancers, in newly invented liposome. When preclinical studies in mice were conducted using a drug where topotecan was encapsulated in liposomes (development number: FF-10850), in addition to confirming high tumor shrinking effects, improved pharmacological efficacy was demonstrated when administered in combination with an immune checkpoint inhibitor*2 , with prolonged survival compared to monotherapy. Going forward, based on the results […]
-
FUJIFILM Corporation (President: Kenji Sukeno) has announced the drug release mechanism of continuous action in tumors for the anti-cancer agent FF-10832, currently undergoing Phase I clinical trials in the United States. In addition, it has also been observed that improved pharmacological efficacy is demonstrated when administered in combination with an immune checkpoint inhibitor*1, with prolonged survival compared to monotherapy. These research results have been clarified through preclinical study in mice. FF-10832 is a liposome-based agent in which gemcitabine*2, an […]
-
FUJIFILM ANNOUNCES LAUNCH OF FUJIFILM TOYAMA CHEMICAL
FUJIFILM Corporation (President: Kenji Sukeno) announces the launch of FUJIFILM Toyama Chemical Co., Ltd (President: Junji Okada) on October 1, 2018. The company will engage in the research, development, manufacture and sale of diagnostic and therapeutic drugs. FUJIFILM Toyama Chemical was formed through the merger of TOYAMA CHEMICAL CO., LTD. (Toyama Chemical), a company engaged in the research, development, manufacture and sale of small molecule pharmaceuticals and FUJIFILM RI Pharma Co., Ltd., a company engaged in the […]